EMERITE: Effect of Medical Hypnosis in Virtual Reality on Insomnia Disorders

Sponsor
HypnoVR (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04712825
Collaborator
(none)
50
1
2
19
2.6

Study Details

Study Description

Brief Summary

The prevalence of chronic insomnia is 13.3% in France in 2019 (8.9 million). The consequences for these people are multiple: drowsiness, memory problems, difficulty concentrating, anxiety.

Cognitive and Behavioral Therapy (CBT) is today the reference treatment recommended by the "Haute Autorité de Santé" and the American College of Physicians for chronic insomnia. Today, however, few patients use CBT treatment due to the lack of trained practitioners, the cost of non-reimbursed sessions and the time and involvement that these sessions require.

Several clinical trials have shown beneficial effects of hypnotherapy on sleep disorders. The hypothesis of this work is that the use of hypnosis in virtual reality improves sleep time in patients suffering from insomnia disorders.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive-behavioural therapy
  • Device: HypnoVR® device
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effect of Medical Hypnosis in Virtual Reality on Insomnia Disorders: a Monocentric, Randomized, Open-label, Comparative Study.
Actual Study Start Date :
Dec 8, 2020
Anticipated Primary Completion Date :
Jul 8, 2022
Anticipated Study Completion Date :
Jul 8, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Cognitive-behavioural therapy

Cognitive-behavioural therapy sessions

Behavioral: Cognitive-behavioural therapy
Cognitive-behavioural therapy sessions during 6 weeks of treatment

Experimental: Virtual Reality Hypnosis

Virtual Reality Hypnosis sessions

Device: HypnoVR® device
HypnoVR® sessions during 6 weeks of treatment

Outcome Measures

Primary Outcome Measures

  1. Time to sleep [after 6 weeks of treatment]

    Demonstrate a decrease in time to sleep after treatment, by polysomnography

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patient suffering from insomnia as defined in the Diagnostic and Statistical Manual of Mental Disorders V (DMS-V) and the International Classification of Sleep Disorders.
Exclusion Criteria:
  1. Patient who, in the judgment of the investigator, has a disease that may preclude participation in study procedures.

  2. Minor subject

  3. Subject under judicial protection, guardianship or curatorship

  4. Inability to give informed information about the subject: demented patients, psychotic patients or follow-up for a psychiatric pathology

  5. Unbalanced epilepsy

  6. Hearing and/or visual disorders that contraindicate the use of virtual reality headphones

  7. Patient with a language barrier

  8. Pregnant or breastfeeding patient

  9. Subject in period of exclusion (determined by a previous or current study)

  10. Patient Refusal

  11. Patient currently being treated for depression, alcoholism or drug addiction.

  12. Patient using drug treatment for insomnia not stabilized within 2 weeks prior to the start of the study.

  13. Patient starting psychological, complementary or alternative medicine treatment for insomnia within 2 weeks prior to the start of the study, or during the study.

  14. Patient receiving or having received CBT treatment for insomnia within the last 6 months.

  15. Patient diagnosed with sleep apnea, involuntary limb movement, restless legs syndrome.

  16. Patient with diagnosed medical conditions that cause insomnia: psychotic disorder, bipolar disorder, dementia, generalized anxiety disorder, panic disorder, manic disorder, schizophrenia, cancer.

Contacts and Locations

Locations

Site City State Country Postal Code
1 SELARL Respire Haguenau France 67500

Sponsors and Collaborators

  • HypnoVR

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
HypnoVR
ClinicalTrials.gov Identifier:
NCT04712825
Other Study ID Numbers:
  • HYPNOVR-RIPH-2020-2
First Posted:
Jan 15, 2021
Last Update Posted:
Jan 15, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by HypnoVR
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 15, 2021